Allogenic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for patients with hematologic malignancy and nonmalignant disease. Non-relapse mortality (NRM) may compromise ...
CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that ...
A 2% decline in FVC or DLco significantly increases the risk of death or lung transplant in IPF patients, challenging current clinical thresholds. The study suggests that smaller declines in lung ...
The diffusion capacity of the lung for carbon monoxide (DLCO) is used to measure the body's ability to transfer oxygen across the alveolar-capillary membrane. [1] Internists use this test to identify ...
Diffusing capacity for carbon monoxide (DLCO) change and outcome in advanced non-small cell lung cancer (aNSCLC) treated with immune checkpoint inhibitors (ICIs). This is an ASCO Meeting Abstract from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results